Monoclonal Antibody and Receptor Antagonist Therapy for GVHD

1999 ◽  
pp. 331-368 ◽  
Author(s):  
James L. M. Ferrara ◽  
Ernst Holler ◽  
Bruce Blazar
Keyword(s):  
Monoclonal Antibody ◽  
Receptor Antagonist ◽  
Antagonist Therapy

scholarly journals Role of Biological Response Modifiers in the Treatment of Rheumatoid Arthritis - A Review

1970 ◽  
Vol 18 (1) ◽  
pp. 60-65
Author(s):  
Md Azizul Haque ◽  
ARM Saifuddin Ekram ◽  
Quazi Tarikul Islam
Keyword(s):  
Rheumatoid Arthritis ◽  
Monoclonal Antibody ◽  
Chronic Disease ◽  
Receptor Antagonist ◽  
Disease Progression ◽  
Joint Damage ◽  
Biological Response ◽  
The Past ◽  
Conventional Dmards

Rheumatoid arthritis is a chronic disease with the potential to cause substantial joint damage and disability. During the past 10 years, improved understanding of the pathophysiology of rheumatoid arthritis has led to several key changes in the approach to therapy. Most important of that is the development of some biological agents interfering with the activity of several important cytokines. Infliximab, etanarcept, and adalimumab are TNF blockers, anakinra is IL-1 receptor antagonist, and rituximab is anti CD-20 monoclonal antibody. These newer agents proved to be useful for alleviating symptoms and slowing the disease progression in the patients with RA who have failed to respond to conventional DMARDs.   doi: 10.3329/taj.v18i1.3309 TAJ 2005; 18(1): 60-65

Localization of gastrinomas by selective intra-arterial calcium injection in patients on proton pump inhibitor or H2 receptor antagonist therapy

2005 ◽  
Vol 17 (4) ◽  
pp. 429-433 ◽  
Author(s):  
Waljit S. Dhillo ◽  
Channa N.L. Jayasena ◽  
James E. Jackson ◽  
John A. Lynn ◽  
Stephen R. Bloom ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Receptor Antagonist ◽  
Proton Pump ◽  
H2 Receptor Antagonist ◽  
Antagonist Therapy ◽  
H2 Receptor ◽  
Calcium Injection

Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy

1995 ◽  
Vol 40 (3) ◽  
pp. 590-597 ◽  
Author(s):  
Malcolm Robinson ◽  
Donald R. Campbell ◽  
Stephen Sontag ◽  
Seymour M. Sabesin
Keyword(s):  
Receptor Antagonist ◽  
Reflux Esophagitis ◽  
H2 Receptor Antagonist ◽  
Antagonist Therapy ◽  
H2 Receptor ◽  
Erosive Reflux Esophagitis

Safety of ninety-minute daratumumab infusion

2020 ◽  
pp. 107815522095123
Author(s):  
Jeffrey Lombardi ◽  
Mathieu Boulin ◽  
Madeline Devaux ◽  
Amélie Cransac ◽  
Pauline Pistre ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Clinical Trials ◽  
Receptor Antagonist ◽  
Leukotriene Receptor Antagonist ◽  
Rapid Infusion ◽  
The Third ◽  
Leukotriene Receptor ◽  
Grade 3 ◽  
Infusion Protocol

Purpose Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) are frequent during the first and second infusions. Due to the risks associated with severe IRRs, daratumumab is systematically administered over a period of 3.5 hours. The main objective of this study was to evaluate the safety of a 90-minute daratumumab infusion from the third infusion. Patients and methods All patients who had received two or more doses of daratumumab in monotherapy or in combination with standard infusion rates were included. We excluded patients enrolled in clinical trials. For the rapid infusion protocol, 20% of the dose was administered over 30 minutes and the remaining 80% over 60 minutes. Results From April 1 to May 31, 2019, 25 patients received 53 90-minute infusions of daratumumab. Premedication included corticosteroids, antipyretics, antihistamines, and if necessary a leukotriene receptor antagonist. No grade 3 or grade 4 IRRs were observed. Conclusion From the third infusion, we found that a rapid administration of daratumumab (90 vs 210 minutes) was well tolerated and safe. It would be interesting to test this regimen from the second infusion.

Pharmacokinetic Optimisation of Histamine H1-Receptor Antagonist Therapy

1991 ◽  
Vol 21 (5) ◽  
pp. 372-393 ◽  
Author(s):  
F. Estelle ◽  
R. Simons ◽  
Keith J. Simons
Keyword(s):  
Receptor Antagonist ◽  
H1 Receptor ◽  
Antagonist Therapy ◽  
Histamine H1 Receptor ◽  
H1 Receptor Antagonist
Sign in / Sign up

Export Citation Format

Share Document